461 related articles for article (PubMed ID: 33087117)
21. Warfarin pharmacogenetics.
Johnson JA; Cavallari LH
Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
[TBL] [Abstract][Full Text] [Related]
22. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
23. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
24. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
[TBL] [Abstract][Full Text] [Related]
25. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.
Grossi E; Podda GM; Pugliano M; Gabba S; Verri A; Carpani G; Buscema M; Casazza G; Cattaneo M
Pharmacogenomics; 2014 Jan; 15(1):29-37. PubMed ID: 24329188
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
27. Methods for Predicting Warfarin Dose Requirements.
Saffian SM; Wright DF; Roberts RL; Duffull SB
Ther Drug Monit; 2015 Aug; 37(4):531-8. PubMed ID: 25549208
[TBL] [Abstract][Full Text] [Related]
28. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.
Hernandez W; Gamazon ER; Aquino-Michaels K; Patel S; O'Brien TJ; Harralson AF; Kittles RA; Barbour A; Tuck M; McIntosh SD; Douglas JN; Nicolae D; Cavallari LH; Perera MA
Pharmacogenomics J; 2014 Jun; 14(3):223-8. PubMed ID: 24018621
[TBL] [Abstract][Full Text] [Related]
29. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
30. Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose.
Ma Z; Wang P; Gao Z; Wang R; Khalighi K
PLoS One; 2018; 13(10):e0205872. PubMed ID: 30339708
[TBL] [Abstract][Full Text] [Related]
31. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.
Roper N; Storer B; Bona R; Fang M
J Mol Diagn; 2010 May; 12(3):283-91. PubMed ID: 20228265
[TBL] [Abstract][Full Text] [Related]
32. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
[TBL] [Abstract][Full Text] [Related]
33. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
34. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
[TBL] [Abstract][Full Text] [Related]
35. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
[TBL] [Abstract][Full Text] [Related]
36. Developing Chinese race-specific warfarin dose prediction algorithms.
Gao W; Zhang Z; Guan Z; Chen W; Li Z
Int J Clin Pharm; 2023 Jun; 45(3):731-738. PubMed ID: 36991222
[TBL] [Abstract][Full Text] [Related]
37. Evolutionary Ensemble Learning Algorithm to Modeling of Warfarin Dose Prediction for Chinese.
Tao Y; Chen YJ; Fu X; Jiang B; Zhang Y
IEEE J Biomed Health Inform; 2019 Jan; 23(1):395-406. PubMed ID: 29993619
[TBL] [Abstract][Full Text] [Related]
38. Automated warfarin dose prediction for Asian, American, and Caucasian populations using a deep neural network.
Jahmunah V; Chen S; Oh SL; Acharya UR; Chowbay B
Comput Biol Med; 2023 Feb; 153():106548. PubMed ID: 36652867
[TBL] [Abstract][Full Text] [Related]
39. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
40. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
